Tenax Therapeutics, Inc. shares had a trading volume of 186K in the last trading session. Overall, volume was down 82.71% under the stocks normal daily volume.
Short traders are more bullish on shares of Tenax Therapeutics, Inc. if you consider the downtick in short interest. The stock realized a fall in short interest of -10.65% as of October 13, 2017 from the last reporting period. Short shares fell 136,968 over that timeframe. With short interest at 1,148,941 and short average daily volume at 1,511,680, days to cover is 1.0 and the short interest percentage is 0.04% as of October 13.
These funds have shifted positions in (TENX). Bank Of NEW York Mellon Corp expanded its stake by buying 16,077 shares an increase of 601.9%. Bank Of NEW York Mellon Corp claims 18,748 shares with a value of $14,000. The total value of its holdings increased 600.0%. As of the end of the quarter Citadel Advisors LLC had acquired a total of 5,890 shares growing its position 17.0%. The value of the company’s investment in Tenax Therapeutics, Inc. increased from $19,000 to $30,000 a change of $11,000 for the reporting period.
Creative Planning grew its investment by buying 1,000 shares an increase of 100.0% in the quarter. Creative Planning now holds 2,000 shares valued at $1,000. The value of the position overall is down by 0.0%. Tower Research Capital LLC (trc) augmented its ownership by buying 11,762 shares an increase of 916.0% from 06/30/2016 to 06/30/2017. Tower Research Capital LLC (trc) controls 13,046 shares worth $10,000. The total value of its holdings increased 233.3%.
The company is so far trading down from yesterday’s close of $0.43. Company shares last traded at $0.43 barely above $0.41, the 50 day moving average and well below the 200 day moving average of $0.48. The 50 day moving average went up $0.02 or +5.36% whereas the 200 day moving average was down $-0.05 or -10.88%.
In the last earnings report the EPS was $-1.43 and is expected to be $-0.36 for the current year with 28,236,000 shares outstanding. Next quarter’s EPS is estimated at $-0.08 and the next full year EPS is anticipated to be $-0.28.
Tenax Therapeutics, Inc., launched on April 17, 2008, is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Business’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions..